US researchers highlight the need for follow-up of stage IV non-small-cell lung cancer patients who receive first-line EGFR–tyrosine kinase inhibitor therapy, finding few patients subsequently undergo testing for the T790M mutation.
Use of a patient decision aid video improves informed decision-making about lung cancer screening among people accessing smoking cessation services in the USA, study findings indicate.
Individuals receiving atezolizumab for advanced non-small-cell lung cancer may have worse survival if they are also taking antibiotics or proton pump inhibitors, indicates an analysis of the POPLAR and OAK trials.
Individuals at high risk for developing lung cancer benefit from periodic screening with low-dose computed tomography, indicate the 10-year results from the NELSON trial.
Phase 1b/2 study data show that combining the multitargeted tyrosine kinase inhibitor lenvatinib with pembrolizumab could be a promising treatment option for patients with advanced renal cell carcinoma and selected other advanced solid tumor types.
Adding atezolizumab to carboplatin plus etoposide does not lead to substantially more adverse events than placebo and does not adversely affect health-related quality of life in patients with extensive-stage small-cell lung cancer, IMpower 133 trial data show.
Age should not be a selection factor for treatment decisions in older individuals with non-small-cell lung cancer, suggest two studies published in Cancer.
The multikinase inhibitor crizotinib elicits responses and is well tolerated in people with non-small-cell lung cancer positive for MET exon 14 mutations, shows the PROFILE 1001 trial.
Being overweight or obese is associated with favorable survival outcomes in advanced non-small cell lung cancer patients treated with atezolizumab, research published in JAMA Oncology suggests.
Individuals with advanced non-small-cell lung cancer harboring uncommon EGFR mutations have favorable outcomes in response to osimertinib treatment, say Korean researchers.
Treatment with PD-1 inhibitors offers better overall survival, with comparable tolerability, than does treatment with PD-L1 inhibitors for patients with solid tumors such as non-small-cell lung cancer, suggests a systematic review and meta-analysis.
Adding the potent heat shock protein 90 inhibitor ganetespib to docetaxel does not improve survival among patients with advanced-stage lung adenocarcinoma when used in a second-line setting, results of the GALAXY-2 trial show.
Adding olanzapine 5 mg to standard aprepitant, palonosetron, and dexamethasone antiemetic therapy significantly reduces the number of patients vomiting and needing rescue medication following cisplatin-based chemotherapy, Japanese researchers report.
Patients with EGFR-mutant non-small-cell lung cancer and leptomeningeal metastases respond favorably to high daily doses of osimertinib, phase 1 BLOOM study data suggest.
Individuals with malignant pleural effusion undergoing talc pleurodesis have comparable outcomes regardless of how the talc is delivered, shows a phase 3 trial reported in JAMA.
Sarcopenia in cancer patients taking nivolumab is associated with an increased risk for immune-related acute limiting toxicity, independent of plasma nivolumab concentrations, study results suggest.
Previously untreated patients with stage IV squamous non-small-cell lung cancer report an improved health-related quality of life if carboplatin plus paclitaxel or nab-paclitaxel is supplemented with pembrolizumab, KEYNOTE-407 study results suggest.